Minerva Neurosciences | NERV - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Adma Biologics USD 88.82M 13.19M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Cipla INR 41.64B 6.31B 2025-12
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 63.8M 63.56M 2025-12
CSL USD 4.46B 2.71B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12